Novo Nordisk A/S (FRA:NOV)

Market Cap	260.97B
Revenue (ttm)	40.64B
Net Income (ttm)	14.02B
Shares Out	n/a
EPS (ttm)	3.15
PE Ratio	18.61
Forward PE	16.43
Dividend	1.53 (2.51%)
Ex-Dividend Date	Mar 28, 2025

Volume	874
Average Volume	395
Open	60.35
Previous Close	60.79
Day's Range	58.41 - 60.35
52-Week Range	50.95 - 139.58
Beta	n/a
RSI	46.50
Earnings Date	May 7, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NOV

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK